Abstract
During the last two decades, the studies on ubiquitination in regulating transcription factor NF-κB activation have elucidated the expanding role of ubiquitination in modulating cellular events by non-proteolytic mechanisms, as well as by proteasomal degradation. The significance of ubiquitination has also been recognized in regulating gene transcription, epigenetic modifications, kinase activation, DNA repair and subcellular translocation. This progress has been translated into novel strategies for developing anti-cancer therapeutics, exemplified by the success of the first FDA-approved proteasome inhibitor drug Bortezomib. Here we discuss the current understanding of the ubiquitin-proteasome system and how it is involved in regulating NF-κB signaling pathways in response to a variety of stimuli. We also focus on the recent progress of anti-cancer drug development targeting various steps of ubiquitination process, and the potential of these drugs in cancer treatment as related to their impact on NF-κB activation.
Keywords: Ubiquitin, NF-κB, cancer, therapeutics.
Current Pharmaceutical Design
Title:When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Volume: 19 Issue: 18
Author(s): Zhao-Hui Wu and Yuling Shi
Affiliation:
Keywords: Ubiquitin, NF-κB, cancer, therapeutics.
Abstract: During the last two decades, the studies on ubiquitination in regulating transcription factor NF-κB activation have elucidated the expanding role of ubiquitination in modulating cellular events by non-proteolytic mechanisms, as well as by proteasomal degradation. The significance of ubiquitination has also been recognized in regulating gene transcription, epigenetic modifications, kinase activation, DNA repair and subcellular translocation. This progress has been translated into novel strategies for developing anti-cancer therapeutics, exemplified by the success of the first FDA-approved proteasome inhibitor drug Bortezomib. Here we discuss the current understanding of the ubiquitin-proteasome system and how it is involved in regulating NF-κB signaling pathways in response to a variety of stimuli. We also focus on the recent progress of anti-cancer drug development targeting various steps of ubiquitination process, and the potential of these drugs in cancer treatment as related to their impact on NF-κB activation.
Export Options
About this article
Cite this article as:
Wu Zhao-Hui and Shi Yuling, When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180010
DOI https://dx.doi.org/10.2174/1381612811319180010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of Genomic Insights into Chicken Growth Traits Based on Genome- Wide Association Study and microRNA Regulation
Current Genomics The Pharmacological Treatment of Cachexia
Current Drug Targets Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry CAM Use in Pediatric Oncology
Current Pediatric Reviews The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Recent Advances Using Supercritical Fluid Techniques for Pulmonary Administration of Macromolecules via Dry Powder Formulations
Drug Delivery Letters Parallel Analysis of v-Src Mutant Protein Function Using Reverse Transfection Cell Arrays
Combinatorial Chemistry & High Throughput Screening Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development
Current Drug Targets